SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No:  ) 

SYNTA PHARMACEUTICALS CORP
--------------------------------------------------------
(Name of Issuer) 

Common Stock
--------------------------------------------------------
(Title of Class of Securities) 

87162T206
--------------------------------------------------------
(CUSIP Number) 

December 30, 2011
--------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to 
which this Schedule is filed:

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out 
for a reporting person's initial filing on this form with 
respect to the subject class of securities, and for any 
subsequent amendment containing information which 
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover 
page shall not be deemed to be "filed" for the purpose 
of Section 18 of the Securities Exchange Act of 1934 
("Act") or otherwise subject to the liabilities of that 
section of the Act but shall be subject to all other 
provisions of the Act (however, see the Notes).

CUSIP No.   87162T206

(1)Names of reporting persons. BlackRock, Inc.

(2) Check the appropriate box if a member of a group 
(a) [  ]
(b) [X]

(3) SEC use only

(4) Citizenship or place of organization 

Delaware

Number of shares beneficially owned by each reporting person with:

(5) Sole voting power

4350570

(6) Shared voting power

None

(7) Sole dispositive power

4350570

(8) Shared dispositive power

None

(9) Aggregate amount beneficially owned by each reporting person

4350570

(10) Check if the aggregate amount in Row (9) excludes certain shares 

(11) Percent of class represented by amount in Row 9

8.79%

(12) Type of reporting person 

HC

Item 1.

Item 1(a) Name of issuer: 
-----------------------------------------------------------------------

SYNTA PHARMACEUTICALS CORP

Item 1(b) Address of issuer's principal executive offices:
-----------------------------------------------------------------------

45 Hartwell Ave.
Lexington MA 02421

Item 2.

2(a) Name of person filing: 
----------------------------------------------------------------------
BlackRock, Inc.

2(b) Address or principal business office or, if none, residence: 
-----------------------------------------------------------------------
BlackRock Inc.
40 East 52nd Street
New York, NY 10022

2(c) Citizenship:
--------------------------------------------------------------------
See Item 4 of Cover Page

2(d) Title of class of securities:  
-------------------------------------------------------------------

Common Stock

2(e) CUSIP No.: 
See Cover Page

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), 
check whether the person filing is a: 
[ ] Broker or dealer registered under Section 15 of the Act;
[ ] Bank as defined in Section 3(a)(6) of the Act;
[ ] Insurance company as defined in Section 3(a)(19) of the Act;
[ ] Investment company registered under Section 8 of the 
Investment Company Act of 1940;
[ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
[ ] An employee benefit plan or endowment fund in accordance with 
Rule 13d-1(b)(1)(ii)(F); 
[X] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
[ ] A savings associations as defined in Section 3(b) of the Federal 
Deposit Insurance Act (12 U.S.C. 1813);
[ ] A church plan that is excluded from the definition of an 
investment company under section 3(c)(14) of the Investment Company 
Act of 1940;
[ ] A non-U.S. institution in accordance with 
Rule 240.13d-1(b)(1)(ii)(J);
[ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing 
as a non-U.S. institution in accordance with 
Rule 240.13d-1(b)(1)(ii)(J), please specify the type of 
institution: 

Item 4. Ownership

Provide the following information regarding the aggregate number 
and percentage of the class of securities of the issuer identified in Item 1. 

Amount beneficially owned:

4350570

Percent of class

8.79%

Number of shares as to which such person has:

Sole power to vote or to direct the vote

4350570

Shared power to vote or to direct the vote

None

Sole power to dispose or to direct the disposition of 

4350570

Shared power to dispose or to direct the disposition of

None

Item 5.

Ownership of 5 Percent or Less of a Class. If this statement is being
filed to report the fact that as of the date hereof the reporting person 
has ceased to be the beneficial owner of more than 5 percent of the 
class of securities, check the following [  ].

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

If any other person is known to have the right to receive or the power
to direct the receipt of dividends from, or the proceeds from the sale 
of, such securities, a statement to that effect should be included in 
response to this item and, if such interest relates to more than 5 percent 
of the class, such person should be identified. A listing of the 
shareholders of an investment company registered under the Investment 
Company Act of 1940 or the beneficiaries of employee benefit plan,
pension fund or endowment fund is not required. 

Various persons have the right to receive or the power to direct
the receipt of dividends from, or the proceeds from the sale of 
the common stock of 
SYNTA PHARMACEUTICALS CORP.  
No one person's interest in the common stock of
SYNTA PHARMACEUTICALS CORP
is more than five percent of the total outstanding common shares. 

Item 7. Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on by the Parent Holding 
Company or Control Person.

See Exhibit A

Item 8. Identification and Classification of Members of the Group

If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), 
so indicate under Item 3(j) and attach an exhibit stating the identity 
and Item 3 classification of each member of the group. If a group 
has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), 
attach an exhibit stating the identity of each member of the group. 

Item 9. Notice of Dissolution of Group

Notice of dissolution of a group may be furnished as an exhibit 
stating the date of the dissolution and that all further filings with 
respect to transactions in the security reported on will be filed,
if required, by members of the group, in their individual capacity. 

See Item 5. 

Item 10. Certifications 
By signing below I certify that, to the best of my knowledge and 
belief, the securities referred to above were acquired and are 
held in the ordinary course of business and were not acquired 
and are not held for the purpose of or with the effect of changing 
or influencing the control of the issuer of the securities and were 
not acquired and are not held in connection with or as a participant 
in any transaction having that purpose or effect.

Signature.

After reasonable inquiry and to the best of my knowledge and 
belief, I certify that the information set forth in this statement 
is true, complete and correct.

Dated:  January 20, 2012
BlackRock, Inc.

Signature:  Matthew J. Fitzgerald

-------------------------------------------

Name/Title  Attorney-In-Fact

The original statement shall be signed by each person on whose 
behalf the statement is filed or his authorized representative. 
If the statement is signed on behalf of a person by his authorized 
representative other than an executive officer or general partner 
of the filing person, evidence of the representative's authority to 
sign on behalf of such person shall be filed with the statement, 
provided, however, that a power of attorney for this purpose 
which is already on file with the Commission may be incorporated 
by reference. The name and any title of each person who 
signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute 
Federal criminal violations (see 18 U.S.C. 1001). 

Exhibit A 

Subsidiary                                              

BlackRock Institutional Trust Company, N.A. 
BlackRock Fund Advisors 
BlackRock Advisors, LLC 
BlackRock Capital Management, Inc. 
BlackRock (Luxembourg) S.A. 
BlackRock Investment Management (UK) Limited 
BlackRock Investment Management, LLC

*Entity beneficially owns 5% or greater of the outstanding
shares of the security class being reported on this 
Schedule 13G.
Exhibit B

POWER OF ATTORNEY

The undersigned, BLACKROCK, INC., a corporation duly organized
under the laws of the State of Delaware, United States (the
"Company"), does hereby make, constitute and appoint each of Robert
Connolly, Howard Surloff, Edward Baer, Bartholomew Battista, 
Daniel Waltcher, Karen Clark, John Stelley, Daniel Ronnen, 
Brian Kindelan, Andrew Crain, Con Tzatzakis, John Blevins, 
Rick F. Froio and Matthew Fitzgerald acting severally, as 
its true and lawful attorneys-in-fact, for the purpose of, from time to time,
executing in its name and on its behalf, whether the Company is acting
individually or as representative of others, any and all documents, 
certificates, instruments, statements, other filings and amendments to
the foregoing (collectively, "documents") determined by such person
to be necessary or appropriate to comply with ownership or
control-person reporting requirements imposed by any United States 
or non-United States governmental or regulatory authority, including 
without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any 
amendments to any of the foregoing as may be required to be filed 
with the Securities and Exchange Commission, and delivering, 
furnishing or filing any such documents with the appropriate 
governmental, regulatory authority or other person, and giving and 
granting to each such attorney-in-fact power and authority to act in 
the premises as fully and to all intents and purposes as the Company
might or could do if personally present by one of its authorized 
signatories, hereby ratifying and confirming all that said 
attorney-in-fact shall lawfully do or cause to be done by
virtue hereof. Any such determination by an attorney-in-fact named
herein shall be conclusively evidenced by such person's execution,
delivery, furnishing or filing of the applicable document.

This power of attorney shall expressly revoke the power of attorney
dated October 5, 2011  in respect of the subject matter hereof, shall be
valid from the date hereof and shall remain in full force and effect until
either revoked in writing by the Company, or, in respect of any
attorney-in-fact named herein, until such person ceases to be an
employee of the Company or one of its affiliates.

IN WITNESS WHEREOF, the undersigned has caused this power of
attorney to be executed as of this 30th day of November, 2011.

BLACKROCK, INC.

By:_ /s/ Robert W. Doll, Jr. 
Name: Robert W. Doll, Jr.
Title: Vice Chairman